Crinetics Pharmaceuticals, Inc. is classed by the SEC under Pharmaceutical Preparations (industry code 2834), based in San Diego, CA. In its latest annual figures on file, for the fiscal year ended 2025-12-31, it reported revenue of $8 million and a loss of $465 million (its filed statements).
Pre-revenue companyPharmaceutical PreparationsSan Diego, CAfilings since 20158 of 9 filed, 1 estimated
Three tenses, nine metrics. Unseen metrics stay unseen; the grade never fakes a number. Proxy era: provisional values, marked. Weighed as a pre-revenue company: no meaningful revenue on file yet (industry code 2834), so it is read as a pre-revenue company; the filing read can change it. All three tenses have at least two readings, so the archetype blend applies as printed.
The grade, in three tenses
Headline 5.0 out of ten, 8 of 9 metrics filed and 1 estimated: past 3.2 out of ten, present 4.2 out of ten, future 6.9 out of ten. The past asks what it actually did, the present what it is doing right now, the future what it is set up to do next.
The nine metrics
Surviving crises (past): 2.1 out of ten. 2 warning events since 2017; the latest 2026-09-01. 21st percentile among 497 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Track record (past): 3.4 out of ten. +33.1% a year over 10 filed years; profitable in 0 of 10. 34th percentile among 324 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Shareholder treatment (past): 3.6 out of ten. CrossAssetData estimate 3.6/10, confidence 35 of 100 (one part). 36th percentile among 463 sector filers. A CrossAssetData estimate, not a filed reading: one part, confidence 35 of 100; a filing that carries the missing parts replaces this estimate with the filed reading.
Financial health (present): 5.0 out of ten. ROE -47%: lost 47¢ per shareholder dollar. Leverage 12%: owes 12¢ per asset dollar. 50th percentile among 472 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Industry position (present): 2.6 out of ten. bottom 26% of 314 in its family; net margin -6046.2%. 26th percentile among 314 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Leadership (present): 4.2 out of ten. bottom 42% of 315 in its family for leadership; chief executive since 2018. 42nd percentile among 315 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-09).
Room to expand (future): 5.0 out of ten. bottom 50% of 272 in its family for room to expand. 50th percentile among 272 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Growth drivers (future): 8.9 out of ten. top 11% of 307 in its family for growth drivers. 89th percentile among 307 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Expectations vs reality (future): 5.4 out of ten. top 46% of 234 in its family for expectations against reality. 54th percentile among 234 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
The filing record
Newest annual report: Form 10-K filed 2026-02-26 for the period ended 2025-12-31 (on EDGAR). Newest quarterly report: Form 10-Q filed 2026-08-03 for the period ended 2026-06-30 (on EDGAR). Newest results release: Form 8-K filed 2026-08-03 (on EDGAR). Newest filing: Form 15-12G, 2026-09-11. Filings on record since 2015. Read from EDGAR 2026-10-12.
Where the revenue comes from
Product and service lines in fiscal 2025: Product 70%, License and Service 30%. As tagged in its annual report (Form 10-K, filed 2026-02-26).
Who runs it
Struthers, Richard Scott (President & CEO); Schilke, Tobin (Chief Financial & Infra. Ofcr.); Betz, Stephen F. (Chief Scientific Officer); Kalofonos, Isabel (Chief Commercial Officer); Knight, Jeff E. (Chief Dev. & Operating Officer); Pizzuti, Dana (Chief Med and Dev Officer); Bedrosian, Camille L (director); Deardorf, Caren (director); Fust, Matthew K (director); Nichols, Weston (director); and 3 more. 13 officers and directors have filed their own trades in the last fifteen months, names and titles as filed with the SEC, through 2026-09-30.
Every stock is a company. We grade the company behind the stock. CrossAssetData is a company research product: no investment advice, no price targets, no price predictions; every claim carries its source, and unseen means unseen. The full file draws when the page's script runs: the essentials, the balance sheet, the estimators, the trend, and every filing of the last ten years.